Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials

Каратеев, А. Е.

doi:10.14412/1996-7012-2020-4-111-124

Cited by 15 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In clinical trials, SSFE demonstrated chondroprotective (slowing the progression of osteoarthritis and the growth of osteophytes, reducing the degradation of the articular cartilage matrix), anti-inflammatory, antioxidant, and analgesic effects, and showed significant correction of joint and spinal function and improvement in quality of life [83][84][85][86].…”

Section: Chondroitin Sulphates In the Pathogenetic Therapy Of Systemi...mentioning

confidence: 99%

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Golovach,

Rekalov,

Akimov

et al. 2023

Reumatologia

View full text Add to dashboard Cite

Post-traumatic osteoarthritis (PTOA), a disorder of the synovium, subchondral bone, and cartilage that affects the entire joint, constitutes approximately 12% of all cases of symptomatic osteoarthritis. This review summarizes the pathogenetic mechanisms that underlie the positive influence of chondroitin sulphates (CSs) on PTOA as means of preventive and therapeutic treatment. Mechanisms of PTOA development involve chondrocytes undergoing various forms of cell death (apoptosis, pyroptosis, necroptosis, ferroptosis and/or necrosis). Chondroitin sulphates are a class of glycosaminoglycans that improve the structure and function of cartilage and subchondral bone, which is associated with their ability to decrease the activation of NF-κB and p38 MAPK, and up-regulate Nrf2. Standardized small fish extract (SSFE) is an example of the drugs that can attenuate NF-κB-mediated systemic inflammation, potentially helping to reduce joint inflammation and cartilage degradation, improve joint function, and alleviate pain and disability in patients with these conditions.

show abstract

Section: Chondroitin Sulphates In the Pathogenetic Therapy Of Systemi...mentioning

confidence: 99%

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Golovach,

Rekalov,

Akimov

et al. 2023

Reumatologia

View full text Add to dashboard Cite

show abstract

“…В экспериментальных исследованиях было показано, что структурно-модифицирующий эффект биоактивного концентрата мелких морских рыб при ОА может быть свя-зан с ингибированием экспрессии протеаз, ответственных за каскад деградации ядерного белка аггрекана (экспрессия мРНК ADAMTS4); увеличением синтеза аггрекана и гиалуронана (активация экспрессии мРНК гиалуронан-синтазы, HAS1), а также с активацией основного регулятора транскрипции SOX9, ответственного за предотвращение деградации внеклеточного матрикса. Кроме того, этот препарат способен сдерживать прогрессирование болезни за счет стимуляции пролиферации хондроцитов, активации синтеза внеклеточного матрикса посредством модуляции трансформирующего фактора роста β (ТФРβ), ингибирования гиалуронидазы и окислительного стресса [26,27].…”

unclassified

Analysis of the therapeutic benefits of symptomatic slow acting drugs in osteoarthritis: emphasis on structural-modifying action

Belyaeva

Мазуров

Трофимов

2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The review presents an analysis of the therapeutic effect in osteoarthritis (OA) of the original complex injectable drug Alflutop (bioactive concentrate of small marine fish), which is one of the most widely used symptomatic slow acting drugs (SYSADOA) in Russia. It stimulates the proliferation of chondrocytes, activates the synthesis of the extracellular matrix by modulating transforming growth factor β (TGFβ), inhibits hyaluronidase, oxidative stress and the activity of extracellular expression of proinflammatory cytokine genes – interleukin (IL) 1β, IL6 and IL8 in vitro.The results of prospective clinical studies are presented, which demonstrate the ability of Alflutop to slow down the X-ray progression of OA of the knee joints (inhibit the narrowing of the joint space, the growth of osteophytes and increase the intra-articular concentration of hyaluronic acid), as well as restore the mobility of the hip joints when it is locally introduced into the zone of pathological changes in the articular lip of the acetabulum. Combined therapy with Alflutop leads to activation of reparative processes and significant clinical improvement in patients with post-traumatic OA, and also slows down the progression of chondrodegeneration according to magnetic resonance imaging. The new Alflutop administration regimen for knee OA (2 ml every other day, №10) can increase patient adherence to therapy.The results of clinical studies presented in the review prove the structural-modifying effect of Alflutop in OA of various localization and substantiate its widespread use in this disease in rheumatological, traumatological and orthopedic practice.

show abstract

Evaluation of the efficacy and safety of bioactive concentrate from small sea fish in elderly patients with knee osteoarthritis

Usova

Аверкиева

Летаева

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to evaluate the efficacy and safety of Alflutop (the bioactive concentrate from small sea fish) in patients aged 75 years and older with knee osteoarthritis (OA). Patients and methods. The investigation enrolled 38 patients aged 75 years and older with knee OA (according to the American College of Rheumatology (ACR) criteria, 1986), Kellgren–Lawrence grades II–III, ≥40 mm pain visual analogue scale (VAS), who required continuous non-steroidal anti-inflammatory drug (NSAID) use. All the patients received Alflutop in the standard regimen: a 1-ml intramuscular injection daily for 20 days. The dynamics of pain during movement was assessed using the VAS scale, the WOMAC, and the EQ-5D questionnaire. Comorbidity was determined according to the Charlson comorbidity index, polypharmacy, and the safety of therapy in all the patients. The investigation duration was 8 weeks.Results and discussion. On day 21 of Alflutop therapy, there was a statistically significant reduction in pain, stiffness, and functional insufficiency according to the WOMAC index (p< 0.001) and improvements in quality of life as shown by the EQ-5D questionnaire (p< 0.001); on day 56, the number of NSAID intake days decreased (p=0.005). The findings suggest that there is a high level of comorbidity in the majority (94.7%) of patients. The mean number of drugs taken was 5.0±1.5, which indicates the presence of polypharmacy. No serious or severe adverse events were recorded.Conclusion. The results of the investigation showed the statistically significant efficacy and safety of Alflutop in patients with knee OA in the elderly group.

show abstract

Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials

Cited by 15 publications

References 37 publications

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Molecular mechanisms and potential applications of chondroitin sulphate in managing post-traumatic osteoarthritis

Analysis of the therapeutic benefits of symptomatic slow acting drugs in osteoarthritis: emphasis on structural-modifying action

Evaluation of the efficacy and safety of bioactive concentrate from small sea fish in elderly patients with knee osteoarthritis

Contact Info

Product

Resources

About